ANNUAL REPORT 2018
70Pages

Diagnoses A|\|NUAL REPORT 2018

Financial and Operational Highlights 2 Chief Executive's Review 9 Finance Director's Review 11 Corporate Governance Statement 20 Report of the Remuneration Committee 22 Independent Auditors' Report 23 Consolidated Income Statement 28 Consolidated Statement of Comprehensive Income 29 Consolidated and Company's Statements of Financial Position 30 Consolidated and Company's Statements of Cash Flows 31 Consolidated Statement of Changes in Equity 32 Company Statement of Changes in Equity 33 Notes to the Financial Statements 34 Notice of Annual General Meeting 65

Financial Highlights • Revenue up 2% to £42.5m (2017: £41.6m) • Gross profit broadly flat at £22.7m (2017: £22.9m) • Adjusted EBITDA* up 15% to £10.7m (2017: £9.3m) • Profit before tax £12.2m (2017: £4.3m), over 2.8 times higher • Basic Earnings per share of 2.21p (2017: 0.59p), underlying basic earnings (excluding exceptional items and share based payments) of 1.01p (2017: 0.58p) • Cash generated from operations of £9.9m (2017: £10.1m) • Cash at 31 December 2018 of £10.3m (31 Dec 2017: £8.2m), net cash of £9.4m (31 Dec 2017: £7.0m) * Excluding exceptional items and share based payments...

Background EKF Diagnostics is a global medical diagnostics business with a long history in point-of-care testing and manufacturing reagents for use in central laboratories. Our point-of-care (POC) products, most of which are designed and manufactured in Germany, have a hard earned reputation for ease of use, reliability and accuracy from professionals working in diabetes, blood banking and sports medicine. The POC business is built around a large installed base of analysers each of which generates a regular demand for tests, often for the entire life cycle of the analyser. In 2018 we sold...

Annual Report 2018 | EKF Diagnostics Holdings plc Point-of-Care: Hemoglobin Analysers Product Portfolio The hemoglobin product range within EKF Diagnostics is the largest in terms of revenues and the number of users. A number of OEM arrangements with distribution partners has provided EKF with access to significant geographic markets and industry sectors that complement a strong and loyal customer base. Hemo ControlTM • Uses ‘gold standard’ methodology (reagent filled microcuvettes) • Data management capability; provides a hematocrit calculation • Proven, robust analyser sold worldwide...

Annual Report 2018 | EKF Diagnostics Holdings plc Point-of-Care: Diabetes Analysers Product Portfolio EKF’s Diabetes Care range aims to provide affordable, easy-to-use technology that reduces the costs of long-term healthcare of the diabetic and pre-diabetic population. Diabetes has been at the core of EKF’s strategy for over a decade starting with the early models of the Biosen glucose analysers. Later, Quo-Test and Quo-Lab were launched to address the diabetes screening market. Although they do not strictly belong within a point-of-care framework, clinical chemistry reagents such as...

Annual Report 2018 | EKF Diagnostics Holdings plc Point-of-Care: Women’s Health & Sports Performance Product Portfolio The Women’s Health product range focuses on specialist diagnostics used to address conditions and complications associated with pregnancy and child birth. Products include the Creamatocrit centrifuge but also the use of our hemoglobin meters that are used in Women and Infant Clinics, pregnancy test kits and HbA1c analysers used to diagnose gestational diabetes in pregnant women. Sports Performance range is primarily comprised of Lactate Scout 4, a handheld blood analyser...

Annual Report 2018 | EKF Diagnostics Holdings plc Central Laboratory Product Portfolio EKF, through its wholly owned subsidiary Stanbio Laboratory, has had a presence within central laboratory dating back over 50 years. During this time it has built a global customer base for its clinical chemistry reagents that can be used on most open-channel analyser platforms. The Central Laboratory business also includes the manufacture of enzymes, produced at EKF Life Sciences in Elkhart, Indiana. From this facility EKF Life Sciences sells enzymes used in Stanbio’s clinical chemistry portfolio as well...

It is a pleasure to report to shareholders on another successful year for EKF, with record revenue, earnings, and profits. Strategy Since I joined the business in April 2016, the Group has followed a consistent strategy of concentrating on its point-of-care diagnostics and central laboratory reagents business. While the task of simplification of the business was largely completed in 2017, we continue to actively seek cost saving opportunities through improved efficiency and targeted action plans, while seeking to position the business for further growth. Renalytix AI pic In January 2018 we...

Chief Executive’s Review In 2018 we have been highly successful in achieving the operational goals we set ourselves at the beginning of the year. I am pleased to announce that we delivered 6.3% year on year organic growth excluding the effect of the completion of the Saudi Arabian Quo-Test contract which had contributed circa £1.6m more to revenues in 2017 than in 2018. The delivery of replacement revenues through new contract wins and additional organic sales growth has not only mitigated the impact of this source of revenue ending, but has allowed us to maintain overall revenue growth....

reagent, which are up 10% in GBP terms. As mentioned earlier, our project to increase capacity and significantly upgrade our main wet chemistry site in Elkhart, Indiana has continued, and is expected to complete in 2019. The work we have done there has enabled us to sign an exclusive, multi-million dollar agreement with Oragenics, Inc., a Florida-based biopharmaceutical company, for the manufacturing of Oragenics’ lantibiotic bulk drug substances in the United States. Under the collaboration agreement, EKF Diagnostics will manufacture compounds intended for preclinical and early stage...